

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A
(RULE 14a-101)

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

Definium Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.





DEFINIUM THERAPEUTICS, INC.
ONE WORLD TRADE CENTER
SUITE 8500
NEW YORK, NY 10007

V93765-PS2037

Your **Vote** Counts!

DEFINIUM THERAPEUTICS, INC.

2026 Annual General and Special Meeting

Vote by June 10, 2026

11:59 PM ET



You invested in DEFINIUM THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual General and Special Meeting. **This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held virtually on June 11, 2026.**

Get informed before you vote

We encourage you to access and review all of the important information contained in the proxy materials before voting. View the Notice and Proxy Statement and Annual Report on Form 10-K online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting a copy prior to May 28, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number



Vote Virtually during the Meeting*

June 11, 2026
10:00 A.M. Eastern Time

Virtually at:
www.virtualshareholdermeeting.com/DFTX2026

*Please check the proxy materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. The complete proxy materials contain important information and are available at www.ProxyVote.com. Please follow the instructions on the reverse side to access and review the proxy materials and to vote on these important matters.

Voting Items	Board Recommends
1. Election of Directors to hold office until the 2027 annual general meeting of shareholders. Nominees:	
1a. Robert Barrow	✔ For
1b. Suzanne Bruhn, Ph.D.	✔ For
1c. Roger Crystal, M.D.	✔ For
1d. David Gryska	✔ For
1e. Andreas Krebs	✔ For
1f. Carol A. Vallone	✔ For
1g. Roger Adsett	✔ For
2. To appoint KPMG LLP as independent registered public accounting firm (auditor) for the Company until the 2027 annual general meeting of shareholders.	✔ For
3. To consider, and if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Equity Incentive Plan") to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan by 5,000,000 common shares.	✔ For
NOTE: Such other business as may properly come before the shareholder meeting or any adjournment or postponement thereof.	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".